Efonidipine
From Self-sufficiency
File:Efonidipine.png | |
Systematic (IUPAC) name | |
---|---|
2-(phenyl-(phenylmethyl)amino)ethyl 5-(5,5-dimethyl-2-oxo-1,3-dioxa-2λ5-phosphacyclohex-2-yl)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3-carboxylate | |
Clinical data | |
Routes of administration | Oral |
Legal status | |
Legal status |
|
Identifiers | |
CAS Number | 111011-63-3 |
ATC code | none |
PubChem | CID 119171 |
Chemical data | |
Formula | C34H38N3O7P |
Molar mass | 631.65 g/mol[[Script error: No such module "String".]] |
Script error: No such module "collapsible list". |
Efonidipine (INN) is a dihydropyridine calcium channel blocker marketed by Shionogi & Co. of Japan. It was launched in 1995, under the brand name Landel.
It has also been studied in atherosclerosis[1] and acute renal failure.[2]
References
Cite error: Invalid <references>
tag;
parameter "group" is allowed only.
<references />
, or <references group="..." />
- (Japanese) Landel ランデル (PDF) Shionogi & Co. April 2005.
30px | This drug article relating to the cardiovascular system is a stub. You can help ssf by expanding it. |
Categories:
- Pages with script errors
- Pages with broken file links
- Drugs with non-standard legal status
- Infobox drug tracked parameters
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs not assigned an ATC code
- Articles containing unverified chemical infoboxes
- Calcium channel blockers
- Pyridines
- Nitro compounds
- Carboxylate esters
- Dioxaphosphinans
- Cardiovascular system drug stubs
- 2Fix